Envestnet Asset Management Inc Fate Therapeutics Inc Transaction History

Envestnet Asset Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$21.04 - $36.06 $174,358 - $298,829	8,287 Added 93.65%	17,136 $384,000
Q2 2022 Aug 03, 2022	BUY	$17.78 - $42.39 $2,044 - $4,874	115 Added 1.32%	8,849 $219,000
Q1 2022 May 04, 2022	BUY	$29.67 - $60.28 $43,229 - $87,827	1,457 Added 20.02%	8,734 $339,000
Q4 2021 Feb 04, 2022	BUY	$47.84 - $64.34 $348,131 - $468,202	7,277 New	7,277 $426,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.